(Q37791316)

23 August 2017

title

The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder (English)

1 reference

attention deficit hyperactivity disorder

23 August 2017

main subject

0 references

1 reference

Floyd R Sallee

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

23 August 2017

published in

Postgraduate Medicine

1 reference

23 August 2017

volume

122

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

78-87

1 reference

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

ADHD and health services utilization in the national health interview survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

ADHD and comorbid disorders in relation to family environment and symptom severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Comorbid problems in ADHD: degree of association, shared endophenotypes, and formation of distinct subtypes. Implications for a future DSM

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Treatment of Aggressive ADHD in Children and Adolescents: Conceptualization and Treatment of Comorbid Behavior Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Clinical pharmacology of antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Risperidone in the management of agitation and aggression associated with psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

21 January 2018

Neurobiology of ADHD.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Mechanism of action of stimulants in attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Inhibition of both noradrenergic and serotonergic neurons in brain by the α-adrenergic agonist clonidine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

alpha(2)-Adrenoceptor subtypes-mediated physiological, pharmacological actions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

The alpha(2C)-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Association between the alpha-2C-adrenergic receptor gene and attention deficit hyperactivity disorder in a Korean sample

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Differences in psychic performance with guanfacine and clonidine in normotensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Transdermal clonidine: therapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2204

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.09.2204

1 reference

23 August 2017

1 reference